Pregabalin Capsule
Product Images NDC 31722-613

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 31722-613). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure diagram of Pregabalin, showing its molecular components and arrangement relevant to the active ingredient.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing the percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. It compares outcomes for Pregabalin capsules at 25 mg, 100 mg, and 200 mg three times a day, along with a placebo group, illustrating differences in patient pain improvement levels among these treatments.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin 100 mg taken three times a day to placebo, showing distinct curves for each treatment group across the range of pain improvement percentages.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph showing percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. The figure compares the effects of Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day against placebo over a range of pain improvement percentages.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The graph presents patient response distribution across varying pain improvement levels.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph comparing the percent improvement in pain from baseline with the percent of patients improved for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups. The x-axis represents percent improvement in pain, and the y-axis shows the percent of patients improved, illustrating the efficacy difference between the dosages and placebo.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar graph titled 'Study E1' and 'Study E3' showing responder rates (%) on the vertical axis for different treatments, including placebo and various doses of the drug. The horizontal axis lists treatments by dose and frequency. Data bars illustrate responder rates across groups, with statistical significance notes indicated.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line chart comparing seizure reduction (%) from baseline to dose (mg/day) for Pregabalin by study and dosing schedule. Four series are shown: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID, illustrating seizure reduction increasing with higher doses up to 600 mg/day with statistical significance noted (p ≤ 0.0001).*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A bar chart showing responder rates (%) for Pregabalin dosages and placebo. Three groups are displayed: placebo at 22.6%, Pregabalin 2.5 mg/kg/day at 29.1%, and Pregabalin 10 mg/kg/day at 40.6%. Each group’s subject count is noted below the bars (93, 103, and 96, respectively).*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph comparing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 600 mg, 450 mg, and 300 mg daily doses, along with placebo. The graph includes vertical reference lines at 30, 50, and 60 percent improvement marks, illustrating higher patient improvement rates with Pregabalin doses compared to placebo.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A line graph showing the estimated percentage of subjects without LTR over 180 days, comparing Pregabalin and Placebo groups. The graph displays a higher percentage of subjects without LTR in the Pregabalin group throughout the observation period.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph depicting the percent of subjects improved on the vertical axis against the percent improved from baseline to Week 12 on the horizontal axis. Two lines represent Pregabalin and Placebo, showing differences in improvement percentages over time.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph comparing the percentage of subjects improved over time from baseline to week 16 in a study, with Pregabalin and Placebo groups represented by two lines. The x-axis shows the percent improved from baseline to week 16, and the y-axis shows the percent of subjects improved.*

FDA Label Image

Camberlogo (Camberlogo)

FDA Label Image

Pregablin25mgcontainer90 (Pregablin25mgcontainer90)

Pregabalin Capsules 25 mg oral capsule label by Camber Pharmaceuticals, Inc. The label indicates 90 capsules in the package, with storage instructions between 20° to 25°C. It includes a barcode, manufacturer address in Piscataway, NJ, and a note to dispense a Medication Guide to each patient. The product is manufactured for Camber Pharmaceuticals by Hetero Labs Limited, Hyderabad, India.*

FDA Label Image

Pregablin50mgcontainer90 (Pregablin50mgcontainer90)

Label for Pregabalin Capsules 50 mg by Camber Pharmaceuticals, Inc. The label shows the product name, strength, dosage form (capsules), and package count of 90 capsules. It includes storage instructions, contact information, and a barcode. The label also states the product is for prescription use only.*

FDA Label Image

Pregablin75mgcontainer90 (Pregablin75mgcontainer90)

Pregabalin Capsules 75 mg label from Camber Pharmaceuticals, Inc. The label states each capsule contains 75 mg of Pregabalin, with a package size of 90 capsules. Storage instructions specify 20° to 25°C. Manufacturer info includes Camber Pharmaceuticals, Inc., Piscataway, NJ, and Hetero Labs Limited, India.*

FDA Label Image

Pregablin100mgcontainer90 (Pregablin100mgcontainer90)

Label for Pregabalin Capsules 100 mg by Camber Pharmaceuticals, Inc. The label includes dosage strength prominently in orange, indicates package contains 90 capsules, and lists storage instructions and pharmacist dispensing guidance. Manufactured for Camber Pharmaceuticals in Piscataway, NJ, and produced by Hetero Labs Limited, India. The label features a barcode and contact information.*

FDA Label Image

Pregablin150mgcontainer90 (Pregablin150mgcontainer90)

Label for Pregabalin Capsules 150 mg by Camber Pharmaceuticals, Inc. The label includes dosage information, storage instructions, a barcode, and a note directing pharmacists to dispense the accompanying Medication Guide. The package size is 90 capsules. Manufacturing details cite Camber Pharmaceuticals in New Jersey and Hetero Labs Limited in India.*

FDA Label Image

Pregablin200mgcontainer90 (Pregablin200mgcontainer90)

Label for Pregabalin Capsules 200 mg by Camber Pharmaceuticals, Inc. The label indicates 90 capsules in the package, with storage instructions and a medication guide URL. It includes the NDC 31722-615-90 and contact details for the manufacturer and Hetero Labs Limited, India. The label also contains a barcode and pharmacist dispensing instructions.*

FDA Label Image

Pregablin225mgcontainer90 (Pregablin225mgcontainer90)

Label for Pregabalin Capsules 225 mg by Camber Pharmaceuticals, Inc. The label states the product contains 90 capsules. It includes dosage, storage instructions, pharmacist guidance, a barcode, and manufacturer contact information. The label also notes the medication guide availability online and manufacturer details including Hetero Labs Limited, India.*

FDA Label Image

Pregablin300mgcontainer90 (Pregablin300mgcontainer90)

Pregabalin Capsules 300 mg label from Camber Pharmaceuticals, Inc. The label indicates the product contains 90 capsules with each capsule delivering 300 mg of Pregabalin. It includes dosage instructions pointing to the package insert, storage conditions of 20° to 25°C, and safety warnings to keep out of reach of children. The label features the NDC number 31722-617-90 and a barcode. Manufacturing details list Camber Pharmaceuticals in Piscataway, NJ, with packaging by Hetero Labs Limited, Hyderabad, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.